Home Neoplasma 2018 Neoplasma Vol.65, No.2, p.222-227, 2018

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.2, p.222-227, 2018

Title: Cisplatin binds to pre-miR-200b and impairs its processing to mature microRNA
Author: R. MEZENCEV, R. M. WARTELL

Abstract: Cisplatin is an important anticancer drug with a complex mode of action, a variety of possible targets, and numerous resistance mechanisms. While genomic DNA has traditionally been considered to be its most critical anticancer target, several lines of evidence suggest that various RNAs and other biomolecules may play a role in its anticancer mode of action. In this report we demonstrate that cisplatin modifies pre-miR-200b, impairs its processing to mature miRNA, and decreases miR-200b expression in ovarian cancer cells. Considering the role of miR-200b in epithelial-to-mesenchymal transition and cancer chemosensitivity, cisplatin-induced modification of pre-miR-200b and subsequent deregulation of mature miR-200b may, depending on cell context, limit anticancer activity of this important anticancer drug. More gener- ally, precursor miRNAs may be important targets of cisplatin and play a role in this drug’s anticancer activity or modulate cell responses to this drug.

Keywords: cisplatin, pre-miRNA, microRNA, transplatin, miR-200
Published online: 13-Mar-2018
Year: 2018, Volume: 65, Issue: 2 Page From: 222, Page To: 227
doi:10.4149/neo_2018_170116N37
Price: 14.40 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.